Clinical trials: Growth Hormone Disorder
Growth Hormone Deficiency
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
Treatment of children with growth failure due to growth hormone deficiency (GHD). Primary • To evaluate the efficacy and safety of weekly MOD-4023 administration compared to daily Genotropin® administration in Japanese…
- Trial name
- NCT03874013
- Testing
- MOD-4023, Genotropin
- Where
- 46 sites in Japan
- Volunteers
- 44 people
- Sponsor
- OPKO Health, Inc.
Obesity
Effect of DPP4 Inhibition on Growth Hormone Secretion
This study tests the following hypotheses: Aim 1: Test the hypothesis that acute dipeptidyl peptidase 4 (DPP4) inhibition with the currently available anti-diabetic drug, sitagliptin, will increase stimulated growth hormone (GH)…
- Trial name
- NCT01701973
- Testing
- Sitagliptin, Pegvisomant, L-NMMA
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Short Bowel Syndrome
rHGH and Intestinal Permeability in Intestinal Failure
Patients who are being asked to participate in this study have a short small bowel and will be prescribed to take the medication: Zorbtive® ("Zorbtive/Somatropin/(rHGH)").
- Trial name
- rHGH (NCT01380366)
- Testing
- Somatropin, Seven Day Food Diary, Blood Tests (standard of care)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
NAFLD
Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents
Fatty liver disease is an increasing problem in overweight and obese young adults. The purpose of this study is to test the effect of growth hormone on liver fat in obese young adults ages 18-29y with increased liver fat.
- Trial name
- NCT02726542
- Testing
- somatropin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Hormone Deficiency, Aging
Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly
The purpose of the study is to evaluate the effect of a naturally occurring hormone, called Growth Hormone Releasing Hormone (GHRH) on the muscle, bone, and fat tissues of the body.
- Trial name
- NCT01410799
- Testing
- Growth Hormone Releasing Hormone (GHRH )
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Growth Hormone Deficiency
Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency
The study will investigate the effect on growth hormone replacement in patients with isolated growth hormone deficiency on body composition, especially visceral fat mass.
- Trial name
- IGHD (NCT00630487)
- Testing
- Somatropin
- Where
- 2 sites in Germany
- Volunteers
- 9 people
- Sponsor
- Pfizer
Breast Cancer
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
This was a randomized, double-blind, placebo-controlled study conducted in Chinese women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, plus an open-label…
- Trial name
- NCT03671330
- Testing
- Ribociclib, NSAI: Letrozole or Anastrazole, Goserelin
- Where
- 24 sites in China
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Growth Hormone Deficiency
Easypod United States User Trial
This study will help to determine whether an injection log on a recombinant human growth hormone (rhGH) delivery device improves subjects' adherence with injection schedules.
- Trial name
- NCT00689260
- Testing
- easypod
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- EMD Serono
Growth Hormone Deficiency
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
This is a multi-national trial. The goals of the trial are to study the growth response to LUM-201 administration in children with idiopathic growth hormone deficiency (GHD) previously treated with daily rhGH for 12 months in the…
- Trial name
- OraGrowtH213 (NCT05250063)
- Testing
- LUM-201
- Where
- 10 sites in United States, Poland
- Volunteers
- 15 people
- Sponsor
- Lumos Pharma
Growth Hormone Disorder, Adult Growth Hormone Deficiency
A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
This trial is conducted in Asia. The aim of this trial is to evaluate the safety of once weekly dosing of somapacitan (NNC0195-0092) and daily Norditropin® FlexPro® for 52 weeks in previously human growth hormone treated Japanese…
- Trial name
- NCT03075644
- Testing
- somapacitan, Norditropin
- Where
- 12 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.
The diagnosis of growth hormone deficiency (GHD) in adults is established by laboratory testing in patients with an appropriate clinical history of hypothalamic pituitary disease.
- Trial name
- NCT00448747
- Testing
- AEZS-130 (formerly ARD-07), L-ARG+GHRH
- Where
- 13 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- AEterna Zentaris
Fibromyalgia
Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
The purpose of this study is to evaluate the efficacy of recombinant human growth hormone (r-hGH) treatment in severe fibromyalgia subjects with growth axis dysfunction.
- Trial name
- NCT00933686
- Testing
- Saizen®
- Where
- Spain
- Volunteers
- 113 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer
Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy
The study is a prospective, multicenter, observational study to evaluate PRO and physical activity using smartphone-based application and wearable device in Japanese patients with HR+/HER2- advanced breast cancer (ABC).
- Trial name
- JBCRG-26 (NCT04736576)
- Testing
- Wearable device
- Where
- 20 sites in Japan
- Volunteers
- 99 people
- Sponsor
- Pfizer
Growth Hormone Deficiency, Endocrine System Diseases
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control.
- Conditions
- Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Trial name
- foresiGHt (NCT04615273)
- Testing
- Lonapegsomatropin, Somatropin
- Where
- 113 sites in United States, Armenia and 22 more
- Volunteers
- 264 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
Cystic Fibrosis
Growth Hormone Therapy for Wasting in Cystic Fibrosis
Our hypothesis is that Growth Hormone (GH) will not only target the peripheral tissue to stimulate weight and muscle growth which will maximize nutritional potential and improve overall quality of life.
- Trial name
- NCT00803179
- Testing
- Nutropin AQ
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Massachusetts, Worcester
Growth Hormone Deficiency (GHD)
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
A six month study of ACP-001, a long-acting growth hormone product, versus standard human growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone (hGH) will be given on a daily basis.
- Trial name
- NCT01947907
- Testing
- ACP-001, Human Growth Hormone
- Where
- 36 sites in Belarus, Bulgaria and 12 more
- Volunteers
- 53 people
- Sponsor
- Ascendis Pharma A/S
Growth Hormone Deficiency
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
This is a Phase IV, open label, case-controlled, observational study to evaluate the age-adjusted cumulative height velocity in pre-pubertal isolated growth hormone deficient (IGHD) and idiopathic short stature (ISS) participants…
- Trial name
- NCT01243892
- Testing
- NuSpin, Somatropin
- Where
- 14 sites in United States
- Volunteers
- 18 people
- Sponsor
- Genentech, Inc.
Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID)
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
This study will evaluate the safety and effectiveness of insulin-like growth factor-1 (IGF-1) to treat patients with X-linked severe combined immunodeficiency (XSCID).
- Conditions
- Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
- Trial name
- NCT00490100
- Testing
- Increlex
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Growth Hormone Deficiency
Adult Growth Hormone Deficiency and Cardiovascular Risk
This protocol will assess the cardiovascular risk associated with growth hormone deficiency in adults. We will use multiple modalities to assess risk for heart attacks or strokes including blood work, ultrasound, MRI and…
- Trial name
- NCT00720902
- Testing
- Blood draws, growth hormone releasing hormone (GHRH) & arginine, Carotid ultrasound
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Columbia University